POMPANO BEACH, Fla., Oct. 28, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. BSEM, a number one MedTech firm centered on the event, manufacture, and commercialization of placental-derived biologics for superior wound care, declares that it’s going to launch its Third quarter 2024 monetary outcomes on Tuesday, November 12, 2024, and host a convention name and webcast at 4:30 PM ET to debate the outcomes.
The webcast will function an outline of the quarter from Jason Matuszewski, CEO, and Michael Fortunato, CFO. To register for the occasion, please click on HERE.
Convention Name & Webcast Data:
- Convention ID: 9695874
- USA / Worldwide Toll: +1 (646) 307-1963
- USA – Toll-Free: (800) 715-9871
- Canada – Toronto: (647) 932-3411
- Canada – Toll-Free: (800) 715-9871
- Webcast Hyperlink:
The stay and archived webcast of the decision may even be out there on the BioStem Applied sciences web site below the Buyers part or by clicking HERE.
About BioStem Applied sciences, Inc. BSEM: BioStem Applied sciences is a number one innovator centered on harnessing the pure properties of perinatal tissue within the growth, manufacture, and commercialization of allografts for regenerative therapies. The Firm is concentrated on manufacturing merchandise that change lives, leveraging its proprietary BioREtain® processing methodology. BioREtain® has been developed by making use of the most recent analysis in regenerative medication, centered on sustaining progress elements and preserving tissue construction. BioStem Applied sciences’ high quality administration system and normal working procedures have been reviewed and accredited by the American Affiliation of Tissue Banks (“AATB”). These methods and procedures are established per present Good Tissue Practices (“cGTP”) and present Good Manufacturing Processes (“cGMP”). Our portfolio of high quality manufacturers consists of AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Every BioStem Applied sciences placental allograft is processed on the Firm’s FDA registered and AATB accredited website in Pompano Seaside, Florida. For extra data go to biostemtechnologies.com and comply with us on Twitter and Linkedin.
Be a part of BioStem’s Distribution Listing & Social Media:
To comply with the most recent developments at BioStem, sign-up to the Firm’s e-mail distribution record HERE, and comply with us on Twitter and LinkedIn.
Ahead-Wanting Statements: Aside from statements of historic reality, this launch additionally incorporates forward-looking statements inside the that means of the Non-public Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future occasions. Ahead-looking statements could also be recognized utilizing phrases reminiscent of “forecast,” “intend,” “search,” “goal,” “anticipate,” “imagine,” “count on,” “estimate”, “plan,” “outlook,” and “venture” and different related expressions that predict or point out future occasions or tendencies or that aren’t statements of historic issues. Ahead-looking statements with respect to the operations of the Firm, methods, prospects and different features of the enterprise of the Firm are primarily based on present expectations which are topic to recognized and unknown dangers and uncertainties, which might trigger precise outcomes or outcomes to vary materially from expectations expressed or implied by such forward-looking statements. These elements embrace, however are usually not restricted to: (1) the impression of any adjustments to the reimbursement ranges for the Firm’s merchandise; (2) the Firm faces vital and persevering with competitors, which might adversely have an effect on its enterprise, outcomes of operations and monetary situation; (3) speedy technological change might trigger the Firm’s merchandise to grow to be out of date and if the Firm doesn’t improve its product choices via its analysis and growth efforts, it could be unable to successfully compete;(4) to be commercially profitable, the Firm should persuade physicians that its merchandise are protected and efficient options to current remedies and that its merchandise ought to be used of their procedures; (5) the Firm’s potential to lift funds to develop its enterprise; (6) the Firm has incurred vital losses since inception and will incur losses sooner or later; (7) adjustments in relevant legal guidelines or laws; (8) the chance that the Firm could also be adversely affected by different financial, enterprise, and/or aggressive elements; (9) the Firm’s potential to keep up manufacturing of its merchandise in enough portions to satisfy demand; and (10) the COVID-19 pandemic and its impression, if any, on the Firm’s fiscal situation and outcomes of operations; You’re cautioned to not place undue reliance upon any forward-looking statements, which communicate solely as of the date made. Though it could voluntarily achieve this occasionally, the Firm undertakes no dedication to replace or revise the forward-looking statements, whether or not on account of new data, future occasions or in any other case, besides as required by relevant securities legal guidelines.
BioStem Applied sciences, Inc.
Cellphone: 954-380-8342
Web site:
E-Mail: [email protected]
Twitter: @BSEM_Tech
Fb: BioStemTechnologies
PCG Advisory
Jeff Ramson
[email protected]
646-863-6893
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
